The risk of common hypoglycemic and antihypertensive medications and COVID-19 : A 2-sample Mendelian randomization study
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: It has been reported that diabetes and hypertension increase the adverse outcomes of coronavirus disease 2019 (COVID-19). Aside from the inherent factors of diabetes and hypertension, it remains unclear whether antidiabetic or antihypertensive medications contribute to the increased adverse outcomes of COVID-19. The effect of commonly used antidiabetic and antihypertensive medications on COVID-19 outcomes has been inconsistently concluded in existing observational studies. Conducting a systematic study on the causal relationship between these medications and COVID-19 would be beneficial in guiding their use during the COVID-19 pandemic.
METHODS: We employed the 2-sample Mendelian randomization approach to assess the causal relationship between 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and 3 commonly used antihypertensive medications (calcium channel blockers [CCB], ACE inhibitors, β-receptor blockers [BB]), and COVID-19 susceptibility, hospitalization, and severe outcomes. The genetic variations in the drug targets of the 5 antidiabetic medications and 3 antihypertensive medications were utilized as instrumental variables. European population-specific genome-wide association analysis (GWAS) data on COVID-19 from the Host Genetics Initiative meta-analyses were obtained, including COVID-19 susceptibility (n = 2597,856), COVID-19 hospitalization (n = 2095,324), and COVID-19 severity (n = 1086,211). The random-effects inverse variance-weighted estimation method was employed as the primary assessment technique, with various sensitivity analyses conducted to evaluate heterogeneity and pleiotropy.
RESULTS: There were no potential associations between the genetic variations in the drug targets of the 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and the 3 commonly used antihypertensive medications (CCBs, ACE inhibitors, BBs) with COVID-19 susceptibility, hospitalization, and severity (all P > .016).
CONCLUSION: The findings from this comprehensive Mendelian randomization analysis suggest that there may be no causal relationship between the 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and the 3 commonly used antihypertensive medications (CCBs, ACE inhibitors, BBs) with COVID-19 susceptibility, hospitalization, and severity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
---|---|
Enthalten in: |
Medicine - 103(2024), 6 vom: 09. Feb., Seite e36423 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Ya [VerfasserIn] |
---|
Links: |
---|
Themen: |
Angiotensin-Converting Enzyme Inhibitors |
---|
Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MD.0000000000036423 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368248976 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368248976 | ||
003 | DE-627 | ||
005 | 20240214233306.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240210s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MD.0000000000036423 |2 doi | |
028 | 5 | 2 | |a pubmed24n1293.xml |
035 | |a (DE-627)NLM368248976 | ||
035 | |a (NLM)38335406 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Ya |e verfasserin |4 aut | |
245 | 1 | 4 | |a The risk of common hypoglycemic and antihypertensive medications and COVID-19 |b A 2-sample Mendelian randomization study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.02.2024 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
520 | |a BACKGROUND: It has been reported that diabetes and hypertension increase the adverse outcomes of coronavirus disease 2019 (COVID-19). Aside from the inherent factors of diabetes and hypertension, it remains unclear whether antidiabetic or antihypertensive medications contribute to the increased adverse outcomes of COVID-19. The effect of commonly used antidiabetic and antihypertensive medications on COVID-19 outcomes has been inconsistently concluded in existing observational studies. Conducting a systematic study on the causal relationship between these medications and COVID-19 would be beneficial in guiding their use during the COVID-19 pandemic | ||
520 | |a METHODS: We employed the 2-sample Mendelian randomization approach to assess the causal relationship between 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and 3 commonly used antihypertensive medications (calcium channel blockers [CCB], ACE inhibitors, β-receptor blockers [BB]), and COVID-19 susceptibility, hospitalization, and severe outcomes. The genetic variations in the drug targets of the 5 antidiabetic medications and 3 antihypertensive medications were utilized as instrumental variables. European population-specific genome-wide association analysis (GWAS) data on COVID-19 from the Host Genetics Initiative meta-analyses were obtained, including COVID-19 susceptibility (n = 2597,856), COVID-19 hospitalization (n = 2095,324), and COVID-19 severity (n = 1086,211). The random-effects inverse variance-weighted estimation method was employed as the primary assessment technique, with various sensitivity analyses conducted to evaluate heterogeneity and pleiotropy | ||
520 | |a RESULTS: There were no potential associations between the genetic variations in the drug targets of the 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and the 3 commonly used antihypertensive medications (CCBs, ACE inhibitors, BBs) with COVID-19 susceptibility, hospitalization, and severity (all P > .016) | ||
520 | |a CONCLUSION: The findings from this comprehensive Mendelian randomization analysis suggest that there may be no causal relationship between the 5 commonly used antidiabetic medications (SGLT-2 inhibitors, Sulfonylureas, Insulin analogues, Thiazolidinediones, GLP-1 analogues) and the 3 commonly used antihypertensive medications (CCBs, ACE inhibitors, BBs) with COVID-19 susceptibility, hospitalization, and severity | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a Antihypertensive Agents |2 NLM | |
650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Sulfonylurea Compounds |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
650 | 7 | |a Thiazolidinediones |2 NLM | |
700 | 1 | |a Li, Kai |e verfasserin |4 aut | |
700 | 1 | |a Zeng, Jiaxing |e verfasserin |4 aut | |
700 | 1 | |a Lu, Shunyu |e verfasserin |4 aut | |
700 | 1 | |a Deng, Wangsheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 103(2024), 6 vom: 09. Feb., Seite e36423 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
773 | 1 | 8 | |g volume:103 |g year:2024 |g number:6 |g day:09 |g month:02 |g pages:e36423 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000036423 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 103 |j 2024 |e 6 |b 09 |c 02 |h e36423 |